Sarepta Therapeutics (NASDAQ: SRPT) — Perfil da empresa, notícias e dados financeiros
Sarepta Therapeutics specializes in precision genetic medicines for rare muscular and central nervous system diseases.
Sarepta Therapeutics
Sarepta Therapeutics (NASDAQ:SRPT) is a biotechnology firm that specializes in the discovery and development of precision genetic medicines. The company's primary focus is on treatments for rare diseases, especially those affecting the muscular and central nervous systems. Sarepta Therapeutics is known for its groundbreaking work in Duchenne muscular dystrophy (DMD) therapies, aiming to address the underlying genetic causes of this and other diseases to improve patients' lives significantly. As of now, the company is actively involved in various stages of research, clinical trials, and the development of new drug candidates, with the objective of expanding its portfolio of therapies and making a meaningful impact in areas with unmet medical needs.
Resumo
Operações
Produtos e/ou serviços de Sarepta Therapeutics
- Exondys 51, a treatment for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 51 skipping.
- Vyondys 53, designed for the treatment of DMD in patients who have a specific genetic mutation that can benefit from exon 53 skipping.
- Amondys 45, an antisense oligonucleotide for DMD patients with a mutation amenable to exon 45 skipping.
- Gene therapy program to address genetic mutations in DMD, aiming to deliver a functional dystrophin gene to muscle cells.
- RNA platform targeting the precise modulation of protein expression for various genetic disorders, enabling potential treatments for multiple diseases.
- Casimersen, in development for the treatment of DMD among patients with genetic mutations amenable to exon 45 skipping, further expanding the company'??s DMD exon-skipping portfolio.
equipe executiva do Sarepta Therapeutics
- Ian Michael EstepanPresident & COO
- Ryan H. WongExecutive VP & CFO
- Cristin L. RothfussExecutive VP, General Counsel & Company Secretary
- Douglas S. IngramAdvisor
- Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations
- Michael E. SeverinoCEO & Director
- Rachael PotterChief Scientific Officer
- Tamara ThorntonDirector of Finance, Treasury & Investor Relations
- Alison NasisiExecutive VP & Chief People Officer
- Diane L. BerryExecutive VP and Chief of Global Policy & Advocacy Officer
Principais indicadores financeiros
Resultados divulgados pela Sarepta Therapeutics, em USD.
- Cap. de mercado
- 2 bi
- Receita (TTM)
- 2 bi
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- -6.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,2 bi | -657,8 mi | -713,4 mi | |
| 1,9 bi | 218,1 mi | 235,2 mi | |
| 1,2 bi | -267,8 mi | -536 mi | |
| 933 mi | -536,2 mi | -703,5 mi |